US7041871B1
(en)
*
|
1995-10-10 |
2006-05-09 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5770429A
(en)
*
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US7105159B1
(en)
|
1992-11-05 |
2006-09-12 |
Sloan-Kettering Institute For Cancer Research |
Antibodies to prostate-specific membrane antigen
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
DK0929578T3
(da)
*
|
1996-02-09 |
2003-08-25 |
Abbott Lab Bermuda Ltd |
Humane antistoffer, der binder human TNFalfa
|
US6805869B2
(en)
|
1996-06-12 |
2004-10-19 |
Shanghai Cp Guojian Pharmaceutical Co., Ltd. |
Cellular vaccines and immunotherapeutics and methods for their preparation
|
US7910096B2
(en)
|
1996-11-15 |
2011-03-22 |
Trustees Of Tufts College |
Human neutralizing antibodies against hemolytic uremic syndrome
|
CA2616914C
(en)
|
1996-12-03 |
2012-05-29 |
Abgenix, Inc. |
Egfr-binding antibody
|
GB9823930D0
(en)
*
|
1998-11-03 |
1998-12-30 |
Babraham Inst |
Murine expression of human ig\ locus
|
US7666609B1
(en)
|
1998-12-01 |
2010-02-23 |
Shanghai Cp Guojian Pharmaceutical Co. Ltd. |
Method and composition for diagnosis of melanocytic lesions
|
EE05627B1
(et)
|
1998-12-23 |
2013-02-15 |
Pfizer Inc. |
CTLA-4 vastased inimese monoklonaalsed antikehad
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
CZ302706B6
(cs)
|
1998-12-23 |
2011-09-14 |
Pfizer Inc. |
Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
|
US7883704B2
(en)
*
|
1999-03-25 |
2011-02-08 |
Abbott Gmbh & Co. Kg |
Methods for inhibiting the activity of the P40 subunit of human IL-12
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
US6833268B1
(en)
|
1999-06-10 |
2004-12-21 |
Abgenix, Inc. |
Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
|
MXPA02000961A
(es)
*
|
1999-07-29 |
2003-08-20 |
Medarex Inc |
Anticuerpos monoclonales humanos para antigeno de membrana especifico de la prostata.
|
MXPA02001911A
(es)
|
1999-08-24 |
2003-07-21 |
Medarex Inc |
Anticuerpos ctla-4 humanos y sus usos.
|
AU7491800A
(en)
*
|
1999-09-15 |
2001-04-17 |
Therapeutic Human Polyclonals, Inc. |
Immunotherapy with substantially human polyclonal antibody preparations purifiedfrom genetically engineered birds
|
US7030228B1
(en)
|
1999-11-15 |
2006-04-18 |
Miltenyi Biotec Gmbh |
Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
|
WO2001035735A1
(en)
*
|
1999-11-19 |
2001-05-25 |
Hematech, Llc |
Production of ungulates, preferably bovines that produce human immunoglobulins
|
US7820878B2
(en)
*
|
1999-11-19 |
2010-10-26 |
Kyowa Hakko Kirin Co., Ltd. |
Production of ungulates, preferably bovines that produce human immunoglobulins
|
US7414170B2
(en)
*
|
1999-11-19 |
2008-08-19 |
Kirin Beer Kabushiki Kaisha |
Transgenic bovines capable of human antibody production
|
US7074983B2
(en)
*
|
1999-11-19 |
2006-07-11 |
Kirin Beer Kabushiki Kaisha |
Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin
|
JP2001211882A
(ja)
*
|
2000-01-31 |
2001-08-07 |
Shiyuuji Miyagawa |
移植関連タンパク質をコードするコドン改変型遺伝子
|
US7560534B2
(en)
|
2000-05-08 |
2009-07-14 |
Celldex Research Corporation |
Molecular conjugates comprising human monoclonal antibodies to dendritic cells
|
EP1176200A3
(de)
|
2000-06-20 |
2005-01-12 |
Switch Biotech Aktiengesellschaft |
Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
NZ525664A
(en)
|
2000-11-17 |
2008-08-29 |
Kirin Holdings Kk |
Expression of xenogenous (human) immunoglobulins in cloned, transgenic ungulates
|
ES2405944T3
(es)
|
2000-11-30 |
2013-06-04 |
Medarex, Inc. |
Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos
zadas
|
US20020142397A1
(en)
*
|
2000-12-22 |
2002-10-03 |
Philippe Collas |
Methods for altering cell fate
|
AU2002232858B2
(en)
|
2000-12-22 |
2007-01-11 |
Sab, Llc |
Methods for cloning mammals using reprogrammed donor chromatin or donor cells
|
US7491534B2
(en)
|
2000-12-22 |
2009-02-17 |
Kirin Holdings Kabushiki Kaisha |
Methods for altering cell fate to generate T-cells specific for an antigen of interest
|
JP2005507635A
(ja)
|
2001-02-12 |
2005-03-24 |
メダレックス, インク. |
Fcα受容体(CD89)に対するヒトモノクローナル抗体
|
US7476536B2
(en)
*
|
2001-05-11 |
2009-01-13 |
Kirin Pharma Kabushiki Kaisha |
Artificial human chromosome containing human antibody a light chain gene
|
GB0115256D0
(en)
*
|
2001-06-21 |
2001-08-15 |
Babraham Inst |
Mouse light chain locus
|
US7084257B2
(en)
*
|
2001-10-05 |
2006-08-01 |
Amgen Inc. |
Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
|
AU2002356844C1
(en)
|
2001-10-23 |
2010-03-04 |
Amgen Fremont Inc. |
PSMA antibodies and protein multimers
|
US20050215472A1
(en)
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
US7435871B2
(en)
|
2001-11-30 |
2008-10-14 |
Amgen Fremont Inc. |
Transgenic animals bearing human Igλ light chain genes
|
NZ534205A
(en)
*
|
2001-12-22 |
2006-04-28 |
Antibody A 4 |
Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins
|
CN1638800A
(zh)
|
2002-01-09 |
2005-07-13 |
米德列斯公司 |
抗cd30的人类单克隆抗体
|
ATE431406T1
(de)
|
2002-02-25 |
2009-05-15 |
Genentech Inc |
Neuer typ-1-cytokinrezeptor glm-r
|
EP2314316A1
(en)
|
2002-04-05 |
2011-04-27 |
Amgen, Inc |
Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
|
JP2005529873A
(ja)
|
2002-04-12 |
2005-10-06 |
メダレックス インコーポレイテッド |
Ctla−4抗体を使用した治療の方法
|
GB2387599B
(en)
*
|
2002-04-17 |
2005-08-10 |
Jason Peter Brown |
Methods for producing antibodies
|
CA2484655A1
(en)
|
2002-05-17 |
2003-11-27 |
Hematech, Llc |
Transgenic ungulates capable of human antibody production
|
US7217796B2
(en)
*
|
2002-05-24 |
2007-05-15 |
Schering Corporation |
Neutralizing human anti-IGFR antibody
|
MXPA05002514A
(es)
|
2002-09-06 |
2005-05-27 |
Amgen Inc |
Anticuerpo monoclonal anti-il-1r1 humano terapeutico.
|
AU2003285874A1
(en)
|
2002-10-16 |
2004-05-04 |
Amgen Inc. |
HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
|
WO2004035607A2
(en)
|
2002-10-17 |
2004-04-29 |
Genmab A/S |
Human monoclonal antibodies against cd20
|
AU2003286515A1
(en)
*
|
2002-10-21 |
2004-05-13 |
Regents Of The University Of Minnesota |
Transgenic non-human animals with expanded mature b cell and plasma cell populations
|
JP2006505291A
(ja)
|
2002-11-08 |
2006-02-16 |
ヘマテック,エルエルシー |
プリオンタンパク質活性が低減されたトランスジェニック有蹄動物及びその用途
|
KR101329843B1
(ko)
|
2002-11-15 |
2013-11-14 |
젠맵 에이/에스 |
Cd25에 대한 인간 모노클로날 항체
|
ES2347239T3
(es)
|
2002-12-02 |
2010-10-27 |
Amgen Fremont Inc. |
Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
|
ATE527278T1
(de)
|
2002-12-16 |
2011-10-15 |
Genmab As |
Humane monoklonale antikörper gegen interleukin 8 (il-8)
|
US9259459B2
(en)
|
2003-01-31 |
2016-02-16 |
Celldex Therapeutics Inc. |
Antibody vaccine conjugates and uses therefor
|
CN1767852B
(zh)
|
2003-01-31 |
2010-04-14 |
塞尔德克斯医疗公司 |
抗体疫苗缀合物及其用途
|
EP1613750B1
(en)
|
2003-03-19 |
2015-10-14 |
Amgen Fremont Inc. |
Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
|
CN100409897C
(zh)
|
2003-04-23 |
2008-08-13 |
梅达雷克斯公司 |
1型干扰素拮抗剂在制备治疗患有炎症性肠病的患者的药物中的用途
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
AU2004259398A1
(en)
|
2003-06-27 |
2005-02-03 |
Amgen Fremont Inc. |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
US7579157B2
(en)
|
2003-07-10 |
2009-08-25 |
Hoffmann-La Roche Inc. |
Antibody selection method against IGF-IR
|
EA013614B1
(ru)
*
|
2003-07-15 |
2010-06-30 |
Амджен Инк. |
Изолированное антитело к фактору роста нервов (ngf) и способы его применения
|
EP1498133A1
(en)
|
2003-07-18 |
2005-01-19 |
Aventis Pharma Deutschland GmbH |
Use of a pak inhibitor for the treatment of a joint disease
|
UY28424A1
(es)
*
|
2003-07-22 |
2005-02-28 |
Schering Ag |
Anticuerpos rgi y usos de los mismos.
|
US7396914B2
(en)
|
2003-08-04 |
2008-07-08 |
University Of Massachusetts |
SARS nucleic acids, proteins, antibodies, and uses thereof
|
JP2007521232A
(ja)
|
2003-08-08 |
2007-08-02 |
アブジェニックス・インコーポレーテッド |
副甲状腺ホルモン(pth)に対する抗体およびその使用
|
WO2006101474A1
(en)
|
2005-03-15 |
2006-09-28 |
University Of North Carolina At Chapel Hill |
Methods and compositions for producing active vitamin k-dependent proteins
|
EP2336360A1
(en)
|
2003-09-23 |
2011-06-22 |
University Of North Carolina At Chapel Hill |
Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin K epoxide reductase gene and warfarin dosage
|
ES2344413T3
(es)
|
2003-10-14 |
2010-08-26 |
Baxter International Inc. |
Polipeptido vkorc1 de reciclaje de la vitamina k-epoxido, una diana terapeutica de la cumarina y sus derivados.
|
US7326567B2
(en)
|
2003-11-12 |
2008-02-05 |
Schering Corporation |
Plasmid system for multigene expression
|
EP1533617A1
(en)
|
2003-11-19 |
2005-05-25 |
RMF Dictagene S.A. |
Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
|
US7642341B2
(en)
|
2003-12-18 |
2010-01-05 |
Merck Serono S.A. |
Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
|
PE20050928A1
(es)
*
|
2003-11-21 |
2005-11-08 |
Schering Corp |
Combinaciones terapeuticas de anticuerpo anti-igfr1
|
DK2418220T3
(da)
|
2003-12-10 |
2017-11-06 |
Squibb & Sons Llc |
Interferon-alpha-antistoffer og anvendelser deraf
|
KR101374514B1
(ko)
|
2003-12-10 |
2014-03-13 |
메다렉스, 인코포레이티드 |
Ip―10 항체 및 그의 용도
|
CA2553946C
(en)
|
2004-02-06 |
2019-02-26 |
University Of Massachusetts |
Antibodies against clostridium difficile toxins and uses thereof
|
MXPA06010673A
(es)
|
2004-03-19 |
2007-06-20 |
Amgen Inc |
Reduccion del riesgo de anticuerpos humanos anti-humano a traves de manipulacion del gen v.
|
US7625549B2
(en)
|
2004-03-19 |
2009-12-01 |
Amgen Fremont Inc. |
Determining the risk of human anti-human antibodies in transgenic mice
|
PL1737891T3
(pl)
|
2004-04-13 |
2013-08-30 |
Hoffmann La Roche |
Przeciwciała przeciw selektynie p
|
WO2005103081A2
(en)
|
2004-04-20 |
2005-11-03 |
Genmab A/S |
Human monoclonal antibodies against cd20
|
JP2007533328A
(ja)
|
2004-04-22 |
2007-11-22 |
キリンホールディングス株式会社 |
トランスジェニック動物及びその用途
|
WO2005103086A1
(en)
|
2004-04-23 |
2005-11-03 |
Bundesrepublik Deutschland letztvertreten durch das Robert-Koch-Institut vertreten durch seinen Präsidenten |
Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo
|
EA012622B1
(ru)
|
2004-06-01 |
2009-10-30 |
Домэнтис Лимитед |
Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
|
WO2006002438A2
(en)
|
2004-06-03 |
2006-01-05 |
Medarex, Inc. |
Human monoclonal antibodies to fc gamma receptor i (cd64)
|
LT2662390T
(lt)
|
2004-06-21 |
2017-10-10 |
E. R. Squibb & Sons, L.L.C. |
Interferono-alfa receptoriaus-1 antikūnai ir jų panaudojimas
|
JP5112863B2
(ja)
|
2004-07-01 |
2013-01-09 |
ノヴォ ノルディスク アー/エス |
ヒト抗−kir抗体
|
ME00226B
(me)
|
2004-07-15 |
2011-02-10 |
Medarex Llc |
Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
|
US7709611B2
(en)
|
2004-08-04 |
2010-05-04 |
Amgen Inc. |
Antibodies to Dkk-1
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
MX2007003533A
(es)
|
2004-10-01 |
2007-05-23 |
Medarex Inc |
Metodos de tratar linfomas cd30 positivas.
|
US7785591B2
(en)
*
|
2004-10-14 |
2010-08-31 |
Morphosys Ag |
Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
|
US20080026457A1
(en)
|
2004-10-22 |
2008-01-31 |
Kevin Wells |
Ungulates with genetically modified immune systems
|
CA3079874C
(en)
|
2004-10-22 |
2023-01-03 |
Revivicor, Inc. |
Ungulates with genetically modified immune systems
|
CA2587903A1
(en)
|
2004-11-17 |
2006-05-26 |
Amgen Fremont Inc. |
Fully human monoclonal antibodies to il-13
|
NZ555464A
(en)
|
2004-12-02 |
2010-03-26 |
Domantis Ltd |
Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
|
JP2008521907A
(ja)
*
|
2004-12-03 |
2008-06-26 |
シェーリング コーポレイション |
抗igf1r治療について患者を予め選択するためのバイオマーカー
|
EP1838737B1
(en)
|
2004-12-20 |
2011-04-06 |
Amgen Fremont Inc. |
Binding proteins specific for human matriptase
|
WO2006068953A2
(en)
|
2004-12-21 |
2006-06-29 |
Astrazeneca Ab |
Antibodies directed to angiopoietin-2 and uses thereof
|
MY146381A
(en)
*
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
ES2395953T3
(es)
|
2005-01-26 |
2013-02-18 |
Amgen Fremont Inc. |
Anticuerpos frente a interleucina-1 beta
|
JP2008530244A
(ja)
|
2005-02-18 |
2008-08-07 |
メダレックス, インク. |
フコシル残基を欠くcd30に対するモノクローナル抗体
|
CN101147066A
(zh)
|
2005-03-11 |
2008-03-19 |
塞诺菲-安万特股份有限公司 |
Mgc4504的用途
|
ES2716874T3
(es)
|
2005-03-23 |
2019-06-17 |
Genmab As |
Anticuerpos contra cd38 para el tratamiento del mieloma múltiple
|
CN101222926B
(zh)
*
|
2005-04-15 |
2013-07-17 |
默沙东公司 |
用于治疗或预防癌症的方法和组合物
|
PA8672101A1
(es)
|
2005-04-29 |
2006-12-07 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, métodos y usos
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
US8084198B2
(en)
|
2005-05-11 |
2011-12-27 |
Sanofi-Aventis |
Use of a GIP promoter polymorphism
|
CA2606576A1
(en)
|
2005-05-20 |
2006-11-23 |
Lonza Biologics Plc. |
High-level expression of recombinant antibody in a mammalian host cell
|
EP1893756B1
(en)
*
|
2005-06-08 |
2015-08-12 |
The Regents of The University of California |
Elimination of n-glycolylneuraminic acid from mammalian products for human use
|
AU2006259536A1
(en)
*
|
2005-06-15 |
2006-12-28 |
Schering Corporation |
Anti-IGF1R antibody formulations
|
EP3501537A1
(en)
|
2005-06-30 |
2019-06-26 |
Janssen Biotech, Inc. |
Anti-il23 antibodies, compositions, methods and uses
|
SI1907424T1
(sl)
|
2005-07-01 |
2015-12-31 |
E. R. Squibb & Sons, L.L.C. |
Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
|
NO345593B1
(no)
|
2005-07-18 |
2021-05-03 |
Amgen Inc |
Humane anti-B7RP1 nøytraliserende antistoffer
|
EA016186B1
(ru)
|
2005-09-26 |
2012-03-30 |
Медарекс, Инк. |
Человеческие моноклональные антитела к cd70 и их применение
|
DE102005048898A1
(de)
|
2005-10-12 |
2007-04-19 |
Sanofi-Aventis Deutschland Gmbh |
EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen
|
JP5006330B2
(ja)
|
2005-10-21 |
2012-08-22 |
ノバルティス アーゲー |
Il13に対するヒト抗体および治療的使用
|
CA2629453C
(en)
|
2005-11-10 |
2018-03-06 |
Curagen Corporation |
Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
|
DK1976877T4
(en)
|
2005-11-30 |
2017-01-16 |
Abbvie Inc |
Monoclonal antibodies to amyloid beta protein and uses thereof
|
JP2009518446A
(ja)
|
2005-12-07 |
2009-05-07 |
メダレックス インコーポレーティッド |
Ctla−4抗体投与量漸増レジメン
|
JP5512128B2
(ja)
|
2005-12-08 |
2014-06-04 |
メダレックス・リミテッド・ライアビリティ・カンパニー |
フコシルgm1に対するヒトモノクローナル抗体および抗フコシルgm1を使用するための方法
|
PT1979001E
(pt)
|
2005-12-13 |
2012-07-13 |
Medimmune Ltd |
Proteínas de ligação específicas para factores de crescimento insulínicos e suas aplicações
|
AR056857A1
(es)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
ES2586825T3
(es)
|
2006-01-12 |
2016-10-19 |
Alexion Pharmaceuticals, Inc. |
Anticuerpos para OX-2/CD200 y usos de los mismos
|
EP1976883B1
(en)
|
2006-01-17 |
2012-10-03 |
Medarex, Inc. |
Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
|
EP2001907A2
(en)
*
|
2006-03-21 |
2008-12-17 |
Wyeth a Corporation of the State of Delaware |
Methods and compositions for antagonism of rage
|
WO2007117410A2
(en)
*
|
2006-03-31 |
2007-10-18 |
Medarex, Inc. |
Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
|
WO2007118214A2
(en)
|
2006-04-07 |
2007-10-18 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Antibody compositions and methods for treatment of neoplastic disease
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
TW200815474A
(en)
|
2006-08-03 |
2008-04-01 |
Astrazeneca Ab |
Antibodies alphaVbeta6 and uses thereof
|
WO2008018641A1
(en)
|
2006-08-11 |
2008-02-14 |
Ono Pharmaceutical Co., Ltd. |
Monoclonal antibodies against stromal derived factor-1 (sdf-1)
|
BRPI0714893A2
(pt)
|
2006-09-05 |
2013-05-28 |
Medarex Inc |
anticorpo monoclonal isolado ou uma porÇço de ligaÇço ao seu antÍgeno, um fragmento de anticorpo, um anticorpo mimÉtico, imunoconjugado, composiÇço molÉcula de Ácido nuclÉico isolada, vetor de expressço, cÉlula hospedeira, mÉtodo para preparar um anticorpo anti-bmp2 ou anti-bmp4, mÉtodo para tratar ou prevenir uma doenÇa associada com formaÇço àssea normal e ossificaÇço, hibridoma e metodo para preparar o anticorpo
|
DK2081595T3
(da)
|
2006-09-26 |
2019-07-15 |
Genmab As |
Anti-cd38 plus corticosteroid plus et ikke-corticosteroid kemoterapeutikum til behandling af tumorer
|
AU2007301599B2
(en)
|
2006-09-28 |
2013-01-10 |
Merck Serono S.A. |
Junctional Adhesion Molecule-C (JAM-C) binding compounds and methods of their use
|
ES2625798T3
(es)
|
2006-10-02 |
2017-07-20 |
E. R. Squibb & Sons, L.L.C. |
Anticuerpos humanos que se unen a CXCR4 y usos de los mismos
|
US8613925B2
(en)
|
2006-10-19 |
2013-12-24 |
Csl Limited |
Anti-IL-13Rα1 antibodies and their uses thereof
|
US8618248B2
(en)
|
2006-10-31 |
2013-12-31 |
President And Fellows Of Harvard College |
Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
|
AU2007334264A1
(en)
|
2006-11-15 |
2008-06-26 |
Medarex, Inc. |
Human monoclonal antibodies to BTLA and methods of use
|
HU0700534D0
(en)
*
|
2006-11-24 |
2007-10-29 |
Mezoegazdasagi Biotechnologiai |
Transgenic animal with enhanced immune response and method for the preparation thereof
|
CN101626782B
(zh)
|
2006-12-01 |
2013-03-27 |
梅达雷克斯公司 |
结合cd22的人抗体及其用途
|
CL2007003622A1
(es)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
|
EP2104501B1
(en)
*
|
2006-12-13 |
2014-03-12 |
Merck Sharp & Dohme Corp. |
Methods of cancer treatment with igf1r inhibitors
|
AU2007333098A1
(en)
|
2006-12-14 |
2008-06-19 |
Medarex, Inc. |
Human antibodies that bind CD70 and uses thereof
|
SG177982A1
(en)
*
|
2007-01-16 |
2012-02-28 |
Abbott Lab |
Methods for treating psoriasis
|
EP3248617A3
(en)
|
2007-02-16 |
2018-02-21 |
Merrimack Pharmaceuticals, Inc. |
Antibodies against erbb3 and uses thereof
|
MX2009008706A
(es)
|
2007-02-21 |
2009-09-14 |
Univ Massachusetts |
Anticuerpos humanos contra el virus de la hepatitis c (hcv) y usos de los mismos.
|
JP2010520204A
(ja)
*
|
2007-03-02 |
2010-06-10 |
アムジェン インコーポレイテッド |
腫瘍疾患を治療するための方法および組成物
|
US8501678B2
(en)
|
2007-03-06 |
2013-08-06 |
Atara Biotherapeutics, Inc. |
Variant activin receptor polypeptides and uses thereof
|
TWI573802B
(zh)
|
2007-03-06 |
2017-03-11 |
安美基公司 |
變異之活動素受體多肽及其用途
|
CN103214577B
(zh)
|
2007-03-22 |
2015-09-02 |
生物基因Ma公司 |
特异性结合cd154的包括抗体、抗体衍生物和抗体片段在内的结合蛋白及其用途
|
AU2008234248C1
(en)
|
2007-03-29 |
2015-01-22 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
FI20075278A0
(fi)
|
2007-04-20 |
2007-04-20 |
Biotie Therapies Corp |
Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
|
US20100267934A1
(en)
|
2007-05-31 |
2010-10-21 |
Genmab A/S |
Stable igg4 antibodies
|
WO2008145140A2
(en)
|
2007-05-31 |
2008-12-04 |
Genmab A/S |
Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
|
PT2170956E
(pt)
|
2007-06-15 |
2015-02-05 |
Medigene Ag |
Tratamento de tumores utilizando um anticorpo anti-l1 específico
|
EP2023144A1
(en)
|
2007-08-01 |
2009-02-11 |
Sanofi-Aventis |
Novel AS160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics
|
DK2185719T3
(en)
|
2007-08-02 |
2014-02-17 |
Novimmune Sa |
ANTI-RANTES ANTIBODIES AND PROCEDURES FOR USE THEREOF
|
EP2185692A4
(en)
|
2007-08-10 |
2012-05-02 |
Medarex Inc |
HCO32 AND HCO27 AND RELATED EXAMPLES
|
EA201591355A1
(ru)
|
2007-08-21 |
2016-04-29 |
Амген Инк. |
АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ c-fms ЧЕЛОВЕКА
|
US8865875B2
(en)
|
2007-08-22 |
2014-10-21 |
Medarex, L.L.C. |
Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
|
EP2615114B1
(en)
|
2007-08-23 |
2022-04-06 |
Amgen Inc. |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
PL2769729T3
(pl)
|
2007-09-04 |
2019-09-30 |
Compugen Ltd. |
Polipeptydy i polinukleotydy i ich zastosowanie jako cel dla leków do wytwarzania leków i środków biologicznych
|
GB0717337D0
(en)
|
2007-09-06 |
2007-10-17 |
Ucb Pharma Sa |
Method of treatment
|
TW200918553A
(en)
|
2007-09-18 |
2009-05-01 |
Amgen Inc |
Human GM-CSF antigen binding proteins
|
EP2497783A3
(en)
|
2007-09-26 |
2013-04-17 |
U3 Pharma GmbH |
Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
|
AR068767A1
(es)
|
2007-10-12 |
2009-12-02 |
Novartis Ag |
Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
|
EA201000718A1
(ru)
|
2007-11-02 |
2011-06-30 |
Новартис Аг |
Молекулы и способы, предназначенные для модуляции родственного рецептору липопротеидов низкой плотности белка 6 (lrp6)
|
ES2445755T3
(es)
|
2007-11-07 |
2014-03-05 |
Celldex Therapeutics, Inc. |
Anticuerpos que se unen a células dendríticas y epiteliales humanas 205 (DEC-205)
|
ES2556214T3
(es)
|
2007-11-12 |
2016-01-14 |
U3 Pharma Gmbh |
Anticuerpos para AXL
|
CA2705923A1
(en)
|
2007-11-16 |
2009-05-22 |
Nuvelo, Inc. |
Antibodies to lrp6
|
EP3239178A1
(en)
|
2007-12-14 |
2017-11-01 |
Bristol-Myers Squibb Company |
Binding molecules to the human ox40 receptor
|
ES2483942T5
(es)
|
2007-12-14 |
2017-02-06 |
Novo Nordisk A/S |
Anticuerpos contra NKG2D humano y usos de los mismos
|
CN102037007A
(zh)
|
2008-01-25 |
2011-04-27 |
奥尔胡斯大学 |
选择性外部位点抑制papp-a对igfbp-4的活性
|
EP2641612A1
(en)
|
2008-02-05 |
2013-09-25 |
Bristol-Myers Squibb Company |
Alpha 5 - beta 1 antibodies and their uses
|
EP2274333A4
(en)
|
2008-03-18 |
2011-06-15 |
Abbott Lab |
PROCESS FOR TREATING PSORIASIS
|
EP2105742A1
(en)
|
2008-03-26 |
2009-09-30 |
Sanofi-Aventis |
Use of cathepsin C
|
DK2732823T3
(da)
|
2008-06-25 |
2019-09-16 |
H Lundbeck As |
Modulering af TrpV : Vps10p-domæne-receptorsystemet til behandlingen af smerte
|
EP2815766B1
(en)
|
2008-08-05 |
2017-07-05 |
Novartis AG |
Compositions and methods for antibodies targeting complement protein C5
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
MX2011001409A
(es)
|
2008-08-14 |
2011-03-29 |
Cephalon Australia Pty Ltd |
Anticuerpos anti-il-12/il-23.
|
CA2735900A1
(en)
|
2008-09-19 |
2010-03-25 |
Medimmune, Llc |
Antibodies directed to dll4 and uses thereof
|
DK2342226T3
(en)
|
2008-09-26 |
2016-09-26 |
Dana Farber Cancer Inst Inc |
HUMAN ANTI-PD-1, PD-L1 AND PD-L2 ANTIBODIES AND APPLICATIONS THEREOF
|
AU2009298458B2
(en)
|
2008-09-30 |
2015-10-08 |
Ablexis, Llc |
Non-human mammals for the production of chimeric antibodies
|
WO2010051288A1
(en)
|
2008-10-27 |
2010-05-06 |
Revivicor, Inc. |
Immunocompromised ungulates
|
PT2894165T
(pt)
|
2008-11-10 |
2023-03-17 |
Alexion Pharma Inc |
Métodos e composições para o tratamento de distúrbios associados ao complemento
|
BRPI0920962A2
(pt)
|
2008-11-26 |
2016-07-12 |
Amgen Inc |
variantes de polipeptídeos receptores de activina iib e usos dos mesmos
|
AU2009324092A1
(en)
|
2008-12-03 |
2011-06-23 |
Genmab A/S |
Antibody variants having modifications in the constant region
|
EP2865689A1
(en)
|
2008-12-08 |
2015-04-29 |
Compugen Ltd. |
FAM26F polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
|
UA109633C2
(uk)
|
2008-12-09 |
2015-09-25 |
|
Антитіло людини проти тканинного фактора
|
US8703125B2
(en)
|
2008-12-19 |
2014-04-22 |
H. Lundbeck A/S |
Modulation of the Vps10p-domain receptor family for the treatment of mental and behavioural disorders
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
JP2012513194A
(ja)
|
2008-12-23 |
2012-06-14 |
アストラゼネカ アクチボラグ |
α5β1に向けられた標的結合剤およびその使用
|
EP2219029A1
(en)
|
2009-01-30 |
2010-08-18 |
Sanofi-Aventis |
Test systems, methods and uses involving AS160 protein
|
EA028336B1
(ru)
|
2009-03-05 |
2017-11-30 |
МЕДАРЕКС Л.Л.Си. |
Полностью человеческие антитела, специфические в отношении cadm1
|
WO2010112034A2
(en)
|
2009-04-02 |
2010-10-07 |
Aarhus Universitet |
Compositions and methods for treatment and diagnosis of synucleinopathies
|
CA2762187C
(en)
|
2009-04-08 |
2017-08-01 |
Olle Hernell |
New methods for treatment of inflammatory diseases
|
US9062116B2
(en)
|
2009-04-23 |
2015-06-23 |
Infinity Pharmaceuticals, Inc. |
Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
|
MA33279B1
(fr)
|
2009-04-27 |
2012-05-02 |
Novartis Ag |
Compositions et procédés pour l'augmentation de la croissance des muscles
|
EA201101572A1
(ru)
|
2009-04-27 |
2012-05-30 |
Новартис Аг |
Композиции и способы применения терапевтических антител, специфичных в отношении субъединицы бета1 рецептора il-12
|
PL2448970T3
(pl)
|
2009-05-04 |
2014-12-31 |
Abbvie Res B V |
Przeciwciało przeciwko czynnikowi wzrostu nerwów (NGF) ze zwiększoną stabilnością in vivo
|
CN104974250A
(zh)
|
2009-05-05 |
2015-10-14 |
诺维莫尼公司 |
抗il-17f抗体及其使用方法
|
WO2010151632A1
(en)
|
2009-06-25 |
2010-12-29 |
Bristol-Myers Squibb Company |
Protein purifacation by caprylic acid (octanoic acid ) precipitation
|
HUE055817T2
(hu)
|
2009-07-08 |
2021-12-28 |
Kymab Ltd |
Állatmodellek és terápiás molekulák
|
US20120204278A1
(en)
|
2009-07-08 |
2012-08-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
EP2459594A1
(en)
|
2009-07-31 |
2012-06-06 |
N.V. Organon |
Fully human antibodies to btla
|
WO2011017294A1
(en)
|
2009-08-07 |
2011-02-10 |
Schering Corporation |
Human anti-rankl antibodies
|
WO2011021146A1
(en)
|
2009-08-20 |
2011-02-24 |
Pfizer Inc. |
Osteopontin antibodies
|
EP2293072A1
(en)
|
2009-08-31 |
2011-03-09 |
Sanofi-Aventis |
Use of cathepsin H
|
RU2012114854A
(ru)
*
|
2009-09-14 |
2013-10-27 |
Эбботт Лэборетриз |
Способы лечения псориаза
|
US20120178910A1
(en)
|
2009-09-23 |
2012-07-12 |
Medarex, Inc. |
Cation exchange chromatography (methods)
|
JO3244B1
(ar)
|
2009-10-26 |
2018-03-08 |
Amgen Inc |
بروتينات ربط مستضادات il – 23 البشرية
|
US9588121B2
(en)
|
2009-11-06 |
2017-03-07 |
Go Therapeutics, Inc. |
Method for early detection of cancer
|
RU2012124090A
(ru)
|
2009-11-09 |
2013-12-20 |
Алексион Фармасьютикалз, Инк. |
Реагенты и способы для определения клеток ii типа при pnh
|
TWI630916B
(zh)
|
2009-11-13 |
2018-08-01 |
第一三共歐洲公司 |
供治療或預防人表皮生長因子受體-3(her-3)相關疾病之藥料和方法
|
CA2778953C
(en)
|
2009-11-13 |
2020-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
|
EP3431608A3
(en)
|
2009-11-17 |
2019-02-20 |
E. R. Squibb & Sons, L.L.C. |
Method for enhanced protein production
|
EP3279215B1
(en)
|
2009-11-24 |
2020-02-12 |
MedImmune Limited |
Targeted binding agents against b7-h1
|
US9428586B2
(en)
|
2009-12-01 |
2016-08-30 |
Compugen Ltd |
Heparanase splice variant
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
MX2012008108A
(es)
|
2010-01-11 |
2012-10-03 |
Alexion Pharma Inc |
Biomarcadores de efectos de inmunomodulacion en seres humanos tratados con anticuerpos anti-cd200.
|
EP2533810B1
(en)
|
2010-02-10 |
2016-10-12 |
ImmunoGen, Inc. |
Cd20 antibodies and uses thereof
|
CN103003307B
(zh)
|
2010-03-10 |
2017-08-11 |
根马布股份公司 |
抗c‑MEt的单克隆抗体
|
JP2013522313A
(ja)
|
2010-03-17 |
2013-06-13 |
アボツト・リサーチ・ベー・フエー |
抗神経成長因子(ngf)抗体組成物
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
CN107098958B
(zh)
|
2010-03-26 |
2021-11-05 |
达特茅斯大学理事会 |
Vista调节性t细胞介体蛋白、vista结合剂及其用途
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
LT3248462T
(lt)
|
2010-03-31 |
2024-05-27 |
Ablexis, Llc |
Pelių genų inžinerija, skirta chimerinių antikūnų gamybai
|
EA024701B1
(ru)
|
2010-04-13 |
2016-10-31 |
Селлдекс Терапьютикс Инк. |
Антитела, связывающие cd27 человека, и их применение
|
EP2558497A2
(en)
|
2010-04-15 |
2013-02-20 |
Amgen Inc. |
Human fgf receptor and beta-klotho binding proteins
|
MX353144B
(es)
|
2010-04-20 |
2017-12-20 |
Genmab As |
Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas.
|
US9011852B2
(en)
|
2010-04-30 |
2015-04-21 |
Alexion Pharmaceuticals, Inc. |
Anti-C5a antibodies
|
WO2011140151A1
(en)
|
2010-05-04 |
2011-11-10 |
Dyax Corp. |
Antibodies against epidermal growth factor receptor (egfr)
|
SG185366A1
(en)
|
2010-05-04 |
2012-12-28 |
Merrimack Pharmaceuticals Inc |
Antibodies against epidermal growth factor receptor (egfr) and uses thereof
|
TR201900368T4
(tr)
|
2010-05-04 |
2019-02-21 |
Five Prime Therapeutics Inc |
Csf1r'ye bağlanan antikorlar.
|
ES2949159T3
(es)
|
2010-05-06 |
2023-09-26 |
Novartis Ag |
Composiciones y métodos de uso para anticuerpos terapéuticos de proteína 6 relacionada con lipoproteínas de baja densidad (LRP6)
|
KR20130066631A
(ko)
|
2010-05-06 |
2013-06-20 |
노파르티스 아게 |
치료적 저밀도 지단백질-관련 단백질 6 (lrp6) 다가 항체에 대한 조성물 및 사용 방법
|
CA3051311A1
(en)
|
2010-05-27 |
2011-12-01 |
Genmab A/S |
Monoclonal antibodies against her2
|
CN103153339B
(zh)
|
2010-05-27 |
2021-05-04 |
根马布股份公司 |
针对her2表位的单克隆抗体
|
EP2580243B1
(en)
|
2010-06-09 |
2019-10-16 |
Genmab A/S |
Antibodies against human cd38
|
BR112012031727B1
(pt)
|
2010-06-15 |
2022-03-29 |
Genmab A/S |
Conjugado de droga-anticorpo, composição farmacêutica, e, uso do conjugado de droga- anticorpo
|
AU2011270959A1
(en)
|
2010-06-22 |
2013-01-10 |
Musc Foundation For Research Development |
Antibodies to the C3d fragment of complement component 3
|
EP3327035A1
(en)
|
2010-06-22 |
2018-05-30 |
Precision Biologics Inc. |
Colon and pancreas cancer specific antigens and antibodies
|
WO2012018404A2
(en)
|
2010-08-06 |
2012-02-09 |
U3 Pharma Gmbh |
Use of her3 binding agents in prostate treatment
|
PT2606070T
(pt)
|
2010-08-20 |
2017-03-31 |
Novartis Ag |
Anticorpos para o recetor 3 do fator de crescimento epidérmico (her3)
|
US8999335B2
(en)
|
2010-09-17 |
2015-04-07 |
Compugen Ltd. |
Compositions and methods for treatment of drug resistant multiple myeloma
|
US9068014B2
(en)
|
2010-09-23 |
2015-06-30 |
Precision Biologics, Inc. |
Colon and pancreas cancer peptidomimetics
|
CN103154037A
(zh)
|
2010-10-05 |
2013-06-12 |
诺瓦提斯公司 |
抗IL12Rβ1抗体及它们在治疗自身免疫病和炎性疾病中的用途
|
AU2011313847B2
(en)
|
2010-10-13 |
2016-07-07 |
Janssen Biotech, Inc. |
Human oncostatin M antibodies and methods of use
|
EP2632951B1
(en)
|
2010-10-27 |
2017-08-02 |
Amgen Inc. |
Dkk1 antibodies and methods of use
|
EP2643353A1
(en)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispecific molecules
|
TW201239097A
(en)
|
2010-12-17 |
2012-10-01 |
Sanofi Sa |
MiRNAs in joint disease
|
UY33807A
(es)
|
2010-12-17 |
2012-07-31 |
Sanofi Sa |
miRNAs como indicadores del estado tisular o de enfermedades como osteoartritis
|
TW201238974A
(en)
|
2010-12-17 |
2012-10-01 |
Sanofi Sa |
MiRNAs in joint disease
|
TW201241179A
(en)
|
2010-12-17 |
2012-10-16 |
Sanofi Sa |
MiRNAs in joint disease
|
US9631002B2
(en)
|
2010-12-21 |
2017-04-25 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for producing active vitamin K-dependent proteins
|
CA2824805A1
(en)
|
2011-01-14 |
2012-07-19 |
Five Prime Therapeutics, Inc. |
Il-27 antagonists for treating inflammatory diseases
|
SG10201600531TA
(en)
|
2011-01-24 |
2016-02-26 |
Univ Singapore |
Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
|
AU2012212066A1
(en)
|
2011-02-03 |
2013-08-15 |
Alexion Pharmaceuticals, Inc. |
Use of an anti-CD200 antibody for prolonging the survival of allografts
|
WO2012118693A1
(en)
|
2011-02-28 |
2012-09-07 |
Northshore University Healthsystem |
Methods of diagnosing clostridium difficile infection
|
MX2013010011A
(es)
|
2011-03-01 |
2014-10-24 |
Amgen Inc |
Agentes de unión biespecífica.
|
AU2012239997A1
(en)
|
2011-04-07 |
2013-10-17 |
Amgen Inc. |
Novel EGFR binding proteins
|
WO2012136552A1
(en)
|
2011-04-08 |
2012-10-11 |
H. Lundbeck A/S |
ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
CN105601741A
(zh)
|
2011-04-15 |
2016-05-25 |
卡姆普根有限公司 |
多肽和多核苷酸及其用于治疗免疫相关失调和癌症的用途
|
JP2014514314A
(ja)
|
2011-04-20 |
2014-06-19 |
ゲンマブ エー/エス |
Her2およびcd3に対する二重特異性抗体
|
CN103796678B
(zh)
|
2011-04-20 |
2018-02-27 |
健玛保 |
针对her2的双特异性抗体
|
EP2518157A1
(en)
|
2011-04-26 |
2012-10-31 |
Sanofi |
Test Systems and methods for identifying a compound altering cellular DDR activity
|
EP2702077A2
(en)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
EP2520292A1
(en)
|
2011-05-06 |
2012-11-07 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Use of spirangiens for the treatment or prevention of IL-8 or IL-6 mediated disorders
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
CN107936121B
(zh)
|
2011-05-16 |
2022-01-14 |
埃泰美德(香港)有限公司 |
多特异性fab融合蛋白及其使用方法
|
KR102046666B1
(ko)
|
2011-05-25 |
2019-11-19 |
이나뜨 파르마 |
염증성 장애의 치료를 위한 항-kir 항체
|
US8691231B2
(en)
|
2011-06-03 |
2014-04-08 |
Merrimack Pharmaceuticals, Inc. |
Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
|
US9574002B2
(en)
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
MX2013014847A
(es)
|
2011-06-17 |
2015-01-12 |
Amgen Inc |
Metodo para tratar o aminorar trastornos metabolicos udando clec-2.
|
EP2537532A1
(en)
|
2011-06-22 |
2012-12-26 |
J. Stefan Institute |
Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use
|
AU2012277376B2
(en)
|
2011-06-30 |
2016-11-24 |
Compugen Ltd. |
Polypeptides and uses thereof for treatment of autoimmune disorders and infection
|
HUE040276T2
(hu)
|
2011-07-01 |
2019-02-28 |
Novartis Ag |
Eljárás metabolikus rendellenességek kezelésére
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
US10323081B2
(en)
|
2011-07-06 |
2019-06-18 |
Genmag A/S |
Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chains
|
US9238689B2
(en)
|
2011-07-15 |
2016-01-19 |
Morpho Sys AG |
Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
|
US9156911B2
(en)
|
2011-07-18 |
2015-10-13 |
Amgen Inc. |
Apelin antigen-binding proteins and uses thereof
|
CA2846319A1
(en)
|
2011-09-19 |
2013-03-28 |
Kymab Limited |
Antibodies, variable domains & chains tailored for human use
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
EP2766033B1
(en)
|
2011-10-14 |
2019-11-20 |
Novartis AG |
Antibodies and methods for wnt pathway-related diseases
|
AU2012328322A1
(en)
|
2011-10-27 |
2014-06-12 |
Genmab A/S |
Production of heterodimeric proteins
|
AU2012332590B2
(en)
|
2011-11-01 |
2016-10-20 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
ES2697674T3
(es)
|
2011-11-01 |
2019-01-25 |
Bionomics Inc |
Procedimientos para bloquear el crecimiento de células madre cancerosas
|
AU2012332593B2
(en)
|
2011-11-01 |
2016-11-17 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
CN104053671A
(zh)
|
2011-11-01 |
2014-09-17 |
生态学有限公司 |
治疗癌症的抗体和方法
|
CN104168922A
(zh)
|
2011-11-16 |
2014-11-26 |
安姆根有限公司 |
治疗表皮生长因子缺失突变体viii相关疾病的方法
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
KR20140103135A
(ko)
|
2011-12-05 |
2014-08-25 |
노파르티스 아게 |
Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
|
KR102083957B1
(ko)
|
2011-12-05 |
2020-03-04 |
노파르티스 아게 |
표피 성장 인자 수용체 3 (her3)에 대한 항체
|
CN104220460A
(zh)
|
2011-12-08 |
2014-12-17 |
安姆根有限公司 |
激动人lcat抗原结合蛋白和它们在疗法中的用途
|
EP2793925B1
(en)
|
2011-12-19 |
2019-03-20 |
Amgen Inc. |
Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
|
AU2012356170B2
(en)
|
2011-12-21 |
2016-06-16 |
Novartis Ag |
Compositions and methods for antibodies targeting Factor P
|
CN104185681A
(zh)
|
2012-02-01 |
2014-12-03 |
卡姆普根有限公司 |
C1orf32抗体及其用于治疗癌症的用途
|
PT2812443T
(pt)
|
2012-02-06 |
2019-09-05 |
Inhibrx Inc |
Anticorpos cd47 e métodos de utilização dos mesmos
|
JP6487839B2
(ja)
|
2012-03-15 |
2019-03-20 |
ヤンセン バイオテツク,インコーポレーテツド |
ヒト抗cd27抗体、方法、及び使用
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
PT2841456T
(pt)
|
2012-04-27 |
2018-10-19 |
Novo Nordisk As |
Proteinas de ligação ao antigénio do ligando de cd30 humano
|
EA039663B1
(ru)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
CA2871445C
(en)
|
2012-05-11 |
2020-07-07 |
Five Prime Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
MX2014015195A
(es)
|
2012-06-11 |
2015-02-17 |
Amgen Inc |
Proteinas fijadoras de antigeno antagonistas del receptor de accion dual y sus usos.
|
EP2864352B1
(en)
|
2012-06-22 |
2018-08-08 |
The Trustees Of Dartmouth College |
Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
CN104736174B
(zh)
|
2012-07-06 |
2019-06-14 |
根马布私人有限公司 |
具有三重突变的二聚体蛋白质
|
EP3632462A1
(en)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimeric protein with triple mutations
|
WO2014016737A1
(en)
|
2012-07-24 |
2014-01-30 |
Pfizer Inc. |
Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof
|
AU2013302441B2
(en)
|
2012-08-17 |
2018-05-10 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions and methods for detecting complement activation
|
US10413620B2
(en)
|
2012-08-17 |
2019-09-17 |
The Regents Of The University Of Colorado, A Body Corporate |
Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
|
CN107759690A
(zh)
|
2012-08-31 |
2018-03-06 |
戊瑞治疗有限公司 |
用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
AU2013309506A1
(en)
|
2012-09-02 |
2015-03-12 |
Abbvie Inc. |
Methods to control protein heterogeneity
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
CA2884704C
(en)
|
2012-09-07 |
2023-04-04 |
Randolph J. Noelle |
Vista modulators for diagnosis and treatment of cancer
|
EP3489258A1
(en)
|
2012-11-08 |
2019-05-29 |
Eleven Biotherapeutics, Inc. |
Il-6 antagonists and uses thereof
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
PT2928921T
(pt)
|
2012-12-05 |
2021-04-06 |
Novartis Ag |
Composições e métodos para anticorpos que visam epo
|
EP2935589A1
(en)
|
2012-12-18 |
2015-10-28 |
Novartis AG |
Compositions and methods that utilize a peptide tag that binds to hyaluronan
|
US9938344B2
(en)
|
2012-12-28 |
2018-04-10 |
Precision Biologics, Inc. |
Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
|
KR20160007478A
(ko)
|
2013-01-10 |
2016-01-20 |
젠맵 비. 브이 |
인간 IgG1 Fc 영역 변이체 및 그의 용도
|
EP2948478B1
(en)
|
2013-01-25 |
2019-04-03 |
Amgen Inc. |
Antibodies targeting cdh19 for melanoma
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
SG11201505960VA
(en)
|
2013-02-01 |
2015-08-28 |
Santa Maria Biotherapeutics Inc |
Administration of an anti-activin-a compound to a subject
|
EP4137518A1
(en)
|
2013-02-06 |
2023-02-22 |
Inhibrx, Inc. |
Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
|
UY35315A
(es)
|
2013-02-08 |
2014-09-30 |
Novartis Ag |
Anticuerpos anti-il-17a y su uso en el tratamiento de trastornos autoinmunes e inflamatorios
|
AU2013381687A1
(en)
|
2013-03-12 |
2015-09-24 |
Abbvie Inc. |
Human antibodies that bind human TNF-alpha and methods of preparing the same
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
JOP20140087B1
(ar)
|
2013-03-13 |
2021-08-17 |
Amgen Inc |
بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
|
US8921526B2
(en)
|
2013-03-14 |
2014-12-30 |
Abbvie, Inc. |
Mutated anti-TNFα antibodies and methods of their use
|
CA2904337A1
(en)
|
2013-03-14 |
2014-10-02 |
Amgen Inc. |
Chrdl-1 antigen binding proteins and methods of treatment
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
WO2014159239A2
(en)
|
2013-03-14 |
2014-10-02 |
Novartis Ag |
Antibodies against notch 3
|
WO2014144553A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment
|
WO2014144632A2
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Human pac1 antibodies
|
US9505849B2
(en)
|
2013-03-15 |
2016-11-29 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza M2 and CD3
|
LT2970449T
(lt)
|
2013-03-15 |
2019-11-25 |
Amgen Res Munich Gmbh |
Viengrandės surišančios molekulės, apimančios n galo abp
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
WO2014186877A1
(en)
|
2013-05-24 |
2014-11-27 |
Uger Marni Diane |
FasR ANTIBODIES FOR DIAGNOSTIC AND THERAPEUTIC USE
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
CA2916259C
(en)
|
2013-06-28 |
2024-02-20 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolemia
|
EP3033356B1
(en)
|
2013-08-14 |
2020-01-15 |
Sachdev Sidhu |
Antibodies against frizzled proteins and methods of use thereof
|
BR112016002198A2
(pt)
|
2013-08-14 |
2017-09-12 |
Novartis Ag |
métodos de tratamento de miosite por corpos de inclusão esporádica
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
TW201546284A
(zh)
|
2013-10-01 |
2015-12-16 |
Kymab Ltd |
動物模式及治療分子
|
EP3052640A2
(en)
|
2013-10-04 |
2016-08-10 |
AbbVie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
MX369173B
(es)
|
2013-12-24 |
2019-10-30 |
Janssen Pharmaceutica Nv |
Anticuerpos y fragmentos anti-vista.
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
KR102352573B1
(ko)
|
2014-04-04 |
2022-01-18 |
바이오노믹스 인코포레이티드 |
Lgr5에 결합하는 인간화된 항체들
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
SG10201810507WA
(en)
|
2014-06-06 |
2018-12-28 |
Bristol Myers Squibb Co |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
CN107073109B
(zh)
|
2014-06-11 |
2021-08-06 |
凯西·A·格林 |
Vista激动剂和拮抗剂抑制或增强体液免疫的用途
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗her2表位之單株抗體及其使用之方法
|
SG11201610672YA
(en)
|
2014-06-23 |
2017-01-27 |
Five Prime Therapeutics Inc |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
EP3161001A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Antibodies specific for il-17a fused to hyaluronan binding peptide tags
|
WO2015198243A2
(en)
|
2014-06-25 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long acting proteins
|
WO2015198240A2
(en)
|
2014-06-25 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long acting proteins
|
CA2953807A1
(en)
|
2014-06-26 |
2015-12-30 |
Yale University |
Compositions and methods to regulate renalase in the treatment of diseases and disorders
|
WO2016007414A1
(en)
|
2014-07-08 |
2016-01-14 |
New York University |
Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
|
AU2015286569B2
(en)
|
2014-07-11 |
2021-04-15 |
Genmab A/S |
Antibodies binding AXL
|
CA2956471A1
(en)
|
2014-07-31 |
2016-02-04 |
Amgen Research (Munich) Gmbh |
Optimized cross-species specific bispecific single chain antibody constructs
|
UY36245A
(es)
|
2014-07-31 |
2016-01-29 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
WO2016016415A1
(en)
|
2014-07-31 |
2016-02-04 |
Amgen Research (Munich) Gmbh |
Bispecific single chain antibody construct with enhanced tissue distribution
|
ES2726645T3
(es)
|
2014-08-01 |
2019-10-08 |
Inst Nat Sante Rech Med |
Un anticuerpo anti-CD45RC para usar como medicamento
|
WO2016020882A2
(en)
|
2014-08-07 |
2016-02-11 |
Novartis Ag |
Angiopoetin-like 4 (angptl4) antibodies and methods of use
|
WO2016020880A2
(en)
|
2014-08-07 |
2016-02-11 |
Novartis Ag |
Angiopoietin-like 4 antibodies and methods of use
|
EP3180024B1
(en)
|
2014-08-11 |
2022-05-18 |
University of Massachusetts |
Anti-ospa antibodies and methods of use
|
HRP20220738T1
(hr)
|
2014-08-11 |
2022-08-19 |
Acerta Pharma B.V. |
Terapijske kombinacije inhibitora btk, inhibitora pd-1 i/ili inhibitora pd-l1
|
WO2016040767A2
(en)
|
2014-09-12 |
2016-03-17 |
Amgen Inc. |
Chrdl-1 epitopes and antibodies
|
AR101875A1
(es)
|
2014-09-15 |
2017-01-18 |
Amgen Inc |
Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas
|
WO2016044588A1
(en)
|
2014-09-19 |
2016-03-24 |
The Regents Of The University Of Michigan |
Staphylococcus aureus materials and methods
|
SG10201902924RA
(en)
|
2014-10-03 |
2019-05-30 |
Massachusetts Inst Technology |
Antibodies that bind ebola glycoprotein and uses thereof
|
WO2016059220A1
(en)
|
2014-10-16 |
2016-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tcr-activating agents for use in the treatment of t-all
|
TWI711463B
(zh)
|
2014-10-29 |
2020-12-01 |
美商戊瑞治療有限公司 |
用於癌症之組合療法
|
US10738078B2
(en)
|
2014-11-03 |
2020-08-11 |
Bristol-Myers Squibb Company |
Use of caprylic acid precipitation for protein purification
|
BR112017009297B1
(pt)
|
2014-11-05 |
2024-02-15 |
Annexon, Inc |
Anticorpos antifator de complemento c1q humanizados, composição farmacêutica e kit compreendendo os mesmos, uso terapêutico destes,polinucleotídeo isolado, célula hospedeira isolada, bem como métodos in vitro para detectar sinapses
|
WO2016073894A1
(en)
|
2014-11-07 |
2016-05-12 |
Eleven Biotherapeutics, Inc. |
Therapeutic agents with increased ocular retention
|
SG11201703574VA
(en)
|
2014-11-07 |
2017-05-30 |
Eleven Biotherapeutics Inc |
Improved il-6 antibodies
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
JP6951973B2
(ja)
|
2014-11-12 |
2021-10-20 |
シージェン インコーポレイテッド |
グリカン相互作用化合物及び使用方法
|
NZ731633A
(en)
|
2014-11-21 |
2022-01-28 |
Bristol Myers Squibb Co |
Antibodies against cd73 and uses thereof
|
WO2016090347A1
(en)
|
2014-12-05 |
2016-06-09 |
Immunext, Inc. |
Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
|
EP3945096A1
(en)
|
2014-12-19 |
2022-02-02 |
Regenesance B.V. |
Antibodies that bind human c6 and uses thereof
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
AU2015369854B2
(en)
|
2014-12-22 |
2021-07-01 |
Five Prime Therapeutics, Inc. |
Anti-CSF1R antibodies for treating PVNS
|
SG10202006538TA
(en)
|
2014-12-23 |
2020-08-28 |
Bristol Myers Squibb Co |
Antibodies to tigit
|
WO2016128912A1
(en)
|
2015-02-12 |
2016-08-18 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
|
JP6807859B2
(ja)
|
2015-03-13 |
2021-01-06 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
クロマトグラフィーにおける不純物を取り除くためのアルカリ洗浄の使用
|
US20180105554A1
(en)
|
2015-03-20 |
2018-04-19 |
Bristol-Myers Squibb Company |
Use of dextran sulfate to enhance protein a affinity chromatography
|
US20180105555A1
(en)
|
2015-03-20 |
2018-04-19 |
Bristol-Myers Squibb Company |
Use of dextran for protein purification
|
CN114681608A
(zh)
|
2015-04-13 |
2022-07-01 |
戊瑞治疗有限公司 |
癌症组合疗法
|
EP4276116A3
(en)
|
2015-04-17 |
2024-01-17 |
Amgen Research (Munich) GmbH |
Bispecific antibody constructs for cdh3 and cd3
|
JOP20200116A1
(ar)
|
2015-04-24 |
2017-06-16 |
Amgen Inc |
طرق لعلاج أو الوقاية من الصداع النصفي
|
PE20180926A1
(es)
|
2015-05-29 |
2018-06-08 |
Bristol Myers Squibb Co |
Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral (ox40) y sus usos
|
BR112017021484A2
(pt)
|
2015-06-05 |
2018-07-03 |
Novartis Ag |
anticorpos de direcionamento à proteína morfogenética óssea 9 (bmp9) e métodos para os mesmos
|
BR112017027870A2
(pt)
|
2015-06-24 |
2018-08-28 |
Janssen Pharmaceutica Nv |
anticorpos e fragmentos anti-vista
|
JP2018526977A
(ja)
|
2015-06-29 |
2018-09-20 |
ザ ロックフェラー ユニヴァーシティ |
アゴニスト活性が増強されたcd40に対する抗体
|
EP3319993B1
(en)
|
2015-07-10 |
2020-01-15 |
Genmab A/S |
Axl-specific antibody-drug conjugates for cancer treatment
|
GB201512203D0
(en)
|
2015-07-13 |
2015-08-19 |
Lundbeck & Co As H |
Agents,uses and methods
|
GB201512215D0
(en)
|
2015-07-13 |
2015-08-19 |
Lundbeck & Co As H |
Agents,uses and methods
|
JO3711B1
(ar)
|
2015-07-13 |
2021-01-31 |
H Lundbeck As |
أجسام مضادة محددة لبروتين تاو وطرق استعمالها
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
CN108350072B
(zh)
|
2015-08-03 |
2022-05-24 |
诺华股份有限公司 |
治疗fgf21相关病症的方法
|
US10358503B2
(en)
|
2015-08-13 |
2019-07-23 |
New York University |
Antibody-based molecules selective for the {P}Ser404 epitope of Tau and their uses in the diagnosis and treatment of tauopathy
|
JP6913078B2
(ja)
|
2015-08-13 |
2021-08-04 |
ニューヨーク・ユニバーシティ |
タウの短縮型Asp421エピトープに特異的な、抗体を基にした分子、ならびにタウ異常症の診断および治療におけるそれらの使用
|
EP3347377B1
(en)
|
2015-09-09 |
2021-02-17 |
Novartis AG |
Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
|
AU2016320748B2
(en)
|
2015-09-09 |
2019-05-02 |
Novartis Ag |
Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
|
JP6932700B2
(ja)
|
2015-09-15 |
2021-09-08 |
アムジエン・インコーポレーテツド |
4価の二重特異性抗原結合タンパク質及び4価の四重特異性抗原結合タンパク質、ならびにそれらの使用
|
MA44909A
(fr)
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
WO2017083582A1
(en)
|
2015-11-12 |
2017-05-18 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
WO2017087678A2
(en)
|
2015-11-19 |
2017-05-26 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
RU2021107536A
(ru)
|
2015-11-23 |
2021-07-02 |
Файв Прайм Терапьютикс, Инк. |
Ингибиторы fgfr2 отдельно или в комбинации с иммуностимулирующими агентами в лечении рака
|
EP3383903A1
(en)
|
2015-11-30 |
2018-10-10 |
Bristol-Myers Squibb Company |
Anti human ip-10 antibodies and their uses
|
PT3383920T
(pt)
|
2015-11-30 |
2024-04-15 |
Univ California |
Entrega de carga útil específica para tumores e ativação imune utilizando um anticorpo humano que tem como alvo um antigénio altamente específico da superfície das células tumorais
|
WO2017106578A1
(en)
|
2015-12-15 |
2017-06-22 |
Amgen Inc. |
Pacap antibodies and uses thereof
|
UY37030A
(es)
|
2015-12-18 |
2017-07-31 |
Novartis Ag |
Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
|
NZ743474A
(en)
|
2015-12-23 |
2023-03-31 |
Amgen Inc |
Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
|
HUE052893T2
(hu)
|
2016-01-13 |
2021-05-28 |
Acerta Pharma Bv |
Antifolát és BTK-gátló terápiás kombinációi
|
EP3851457A1
(en)
|
2016-01-21 |
2021-07-21 |
Novartis AG |
Multispecific molecules targeting cll-1
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
PL3411404T3
(pl)
|
2016-02-03 |
2023-02-13 |
Amgen Research (Munich) Gmbh |
Konstrukty dwuswoistych przeciwciał wobec PSMA i CD3 angażujących komórki T
|
US10301391B2
(en)
|
2016-02-03 |
2019-05-28 |
Amgen Research (Munich) Gmbh |
BCMA and CD3 bispecific T cell engaging antibody constructs
|
BR112018016461A2
(pt)
|
2016-02-12 |
2019-10-01 |
Janssen Pharmaceutica Nv |
anticorpos e fragmentos anti-vista, usos dos mesmos e métodos de identificação dos mesmos
|
MX2018010672A
(es)
|
2016-03-04 |
2019-05-27 |
Univ Rockefeller |
Anticuerpos para cumulo de diferenciación 40 (cd40) con actividad agonista mejorada.
|
EA201891983A8
(ru)
|
2016-03-04 |
2020-05-28 |
Бристол-Майерс Сквибб Компани |
Комбинированная терапия антителами к cd73
|
WO2017157305A1
(en)
|
2016-03-15 |
2017-09-21 |
Generon (Shanghai) Corporation Ltd. |
Multispecific fab fusion proteins and use thereof
|
KR102413037B1
(ko)
|
2016-03-15 |
2022-06-23 |
메르사나 테라퓨틱스, 인코포레이티드 |
Napi2b 표적화된 항체-약물 접합체 및 이의 사용 방법
|
JP2019509322A
(ja)
|
2016-03-22 |
2019-04-04 |
バイオノミクス リミテッド |
抗lgr5モノクローナル抗体の投与
|
US10765724B2
(en)
|
2016-03-29 |
2020-09-08 |
Janssen Biotech, Inc. |
Method of treating psoriasis with increased interval dosing of anti-IL12/23 antibody
|
WO2017175058A1
(en)
|
2016-04-07 |
2017-10-12 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
MX2018012469A
(es)
|
2016-04-15 |
2019-07-04 |
Immunext Inc |
Anticuerpos vista antihumanos y uso de los mismos.
|
EA201892362A1
(ru)
|
2016-04-18 |
2019-04-30 |
Селлдекс Терапьютикс, Инк. |
Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
SG11201809793UA
(en)
|
2016-05-09 |
2018-12-28 |
Bristol Myers Squibb Co |
Tl1a antibodies and uses thereof
|
KR102492057B1
(ko)
|
2016-06-15 |
2023-01-26 |
노파르티스 아게 |
골 형태형성 단백질 6(bmp6)의 억제제를 사용한 질병의 치료 방법
|
EP3478721A1
(en)
|
2016-07-01 |
2019-05-08 |
Five Prime Therapeutics, Inc. |
Combined anti tumor therapy with a gitr agonist and cpg
|
GEP20217222B
(en)
|
2016-07-12 |
2021-02-10 |
Lundbeck A/S H |
Antibodies specific for hyperphosphorylated tau and methods of use thereof
|
SG11201900026TA
(en)
|
2016-07-14 |
2019-01-30 |
Bristol Myers Squibb Co |
Antibodies against tim3 and uses thereof
|
AU2017298984B2
(en)
|
2016-07-22 |
2023-08-31 |
Amgen Inc. |
Methods of purifying Fc-containing proteins
|
WO2018029586A1
(en)
|
2016-08-07 |
2018-02-15 |
Novartis Ag |
Mrna-mediated immunization methods
|
US10947268B2
(en)
|
2016-08-12 |
2021-03-16 |
Bristol-Myers Squibb Company |
Methods of purifying proteins
|
WO2018044970A1
(en)
|
2016-08-31 |
2018-03-08 |
University Of Rochester |
Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
|
TW201825674A
(zh)
|
2016-09-09 |
2018-07-16 |
美商艾斯合顧問有限公司 |
表現雙特異性接合分子的溶瘤病毒
|
AU2017336799B2
(en)
|
2016-09-30 |
2023-08-31 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriasis with anti-IL23 specific antibody
|
CU20210030A7
(es)
|
2016-10-13 |
2021-11-04 |
Massachusetts Inst Technology |
Anticuerpos que se unen a la proteína de envoltura del virus zika
|
US11339209B2
(en)
|
2016-11-14 |
2022-05-24 |
Novartis Ag |
Compositions, methods, and therapeutic uses related to fusogenic protein minion
|
EP3538555A1
(en)
|
2016-11-14 |
2019-09-18 |
Amgen Inc. |
Bispecific or biparatopic antigen binding proteins and uses thereof
|
RU2019114679A
(ru)
|
2016-11-15 |
2020-12-17 |
Х. Лундбекк А/С |
Средства, пути применения и способы лечения синуклеопатии
|
MX2019005661A
(es)
|
2016-11-16 |
2019-10-07 |
Janssen Biotech Inc |
Método para tratar la psoriasis con el anticuerpo específico anti-il23.
|
WO2018094143A1
(en)
|
2016-11-17 |
2018-05-24 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
MA47019A
(fr)
|
2016-12-16 |
2021-04-21 |
H Lundbeck As |
Agents, utilisations et procédés
|
US10364286B2
(en)
|
2016-12-22 |
2019-07-30 |
H. Lundbeck A/S |
Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
|
JP7062669B2
(ja)
|
2016-12-23 |
2022-05-06 |
ブリストル-マイヤーズ スクイブ カンパニー |
改善されたバイオアナリシス特性およびバイオプロセシング特性のための、治療用免疫グロブリンg4の設計
|
MA47205A
(fr)
|
2017-01-04 |
2019-11-13 |
H Lundbeck As |
Anticorps spécifiques de la protéine tau hyperphosphorylée pour traiter des maladies oculaires
|
AU2018206279B2
(en)
|
2017-01-06 |
2020-09-03 |
Abl Bio Inc. |
Anti-alpha-syn antibody and use thereof
|
WO2018129451A2
(en)
|
2017-01-09 |
2018-07-12 |
Merrimack Pharmaceuticals, Inc. |
Anti-fgfr antibodies and methods of use
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
EP3573658A4
(en)
|
2017-01-30 |
2021-07-21 |
Janssen Biotech, Inc. |
ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR TREATMENT OF ACTIVE PSORIATIC ARTHRITIS
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
JP2020506947A
(ja)
|
2017-02-07 |
2020-03-05 |
ヤンセン バイオテツク,インコーポレーテツド |
活動性強直性脊椎炎を治療するための抗tnf抗体、組成物、及び方法
|
AU2018218557B9
(en)
|
2017-02-08 |
2021-06-24 |
Novartis Ag |
FGF21 mimetic antibodies and uses thereof
|
JP7136790B2
(ja)
|
2017-02-17 |
2022-09-13 |
ブリストル-マイヤーズ スクイブ カンパニー |
アルファ-シヌクレインに対する抗体およびその使用
|
AU2018226824A1
(en)
|
2017-03-03 |
2019-09-19 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
KR102628323B1
(ko)
|
2017-03-24 |
2024-01-22 |
노바르티스 아게 |
심장질환 예방 및 치료 방법
|
KR102660861B1
(ko)
|
2017-03-30 |
2024-04-25 |
더 존스 홉킨스 유니버시티 |
생체거대분자의 정제를 위한 초분자 고친화성 단백질-결합 시스템
|
CA3057687A1
(en)
|
2017-03-31 |
2018-10-04 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer using anti-gitr antibodies
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
MA48763A
(fr)
|
2017-05-05 |
2020-04-08 |
Amgen Inc |
Composition pharmaceutique comprenant des constructions d'anticorps bispécifiques pour un stockage et une administration améliorés
|
EP3624837A1
(en)
|
2017-05-16 |
2020-03-25 |
Five Prime Therapeutics, Inc. |
Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
|
JOP20190259A1
(ar)
|
2017-05-31 |
2019-10-31 |
Amgen Inc |
بروتينات ربط مولد ضد مضادة لـ jagged1
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
CR20190532A
(es)
|
2017-06-20 |
2020-01-10 |
Amgen Inc |
Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agonistas de glp-1
|
AU2018292579A1
(en)
|
2017-06-28 |
2019-12-05 |
Novartis Ag |
Methods for preventing and treating urinary incontinence
|
US10894833B2
(en)
|
2017-07-20 |
2021-01-19 |
H. Lundbeck A/S |
Agents, uses and methods for treatment
|
US20210346513A1
(en)
|
2017-08-04 |
2021-11-11 |
Amgen Inc. |
Method of conjugation of cys-mabs
|
US20200256880A1
(en)
|
2017-08-16 |
2020-08-13 |
The Broad Institute, Inc. |
Neuronal Assay Method Involving Calcineurin
|
JP7379323B2
(ja)
|
2017-08-18 |
2023-11-14 |
ザ・ジョンズ・ホプキンス・ユニバーシティ |
タンパク質精製のための超分子フィラメント集合体
|
SG11202001606XA
(en)
|
2017-09-13 |
2020-03-30 |
Five Prime Therapeutics Inc |
Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗il12/il23抗體治療狼瘡之安全且有效之方法
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
CA3084049A1
(en)
|
2017-12-05 |
2019-06-13 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
|
EA202091422A1
(ru)
|
2017-12-11 |
2020-08-28 |
Эмджен Инк. |
Способ непрерывного производства продуктов на основе биспецифических антител
|
EP3498293A1
(en)
|
2017-12-15 |
2019-06-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Treatment of monogenic diseases with an anti-cd45rc antibody
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對muc17和cd3之雙特異性抗體構建體
|
CA3087951A1
(en)
|
2018-01-12 |
2019-07-18 |
Amgen Inc. |
Pac1 antibodies and uses thereof
|
SG11202005323SA
(en)
|
2018-01-12 |
2020-07-29 |
Bristol Myers Squibb Co |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|
CN111886255A
(zh)
|
2018-01-12 |
2020-11-03 |
百时美施贵宝公司 |
抗tim3抗体及其用途
|
WO2019171252A1
(en)
|
2018-03-05 |
2019-09-12 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
TW202003565A
(zh)
|
2018-03-23 |
2020-01-16 |
美商必治妥美雅史谷比公司 |
抗mica及/或micb抗體及其用途
|
EP3774882A1
(en)
|
2018-03-29 |
2021-02-17 |
Bristol-Myers Squibb Company |
Methods of purifying monomeric monoclonal antibodies
|
BR112020022265A2
(pt)
|
2018-05-07 |
2021-02-23 |
Genmab A/S |
método para tratar câncer em um indivíduo, e, estojo.
|
KR20210044183A
(ko)
|
2018-05-07 |
2021-04-22 |
젠맵 에이/에스 |
항-pd-1 항체 및 항-조직 인자 항체-약물 접합체의 조합을 사용하여 암을 치료하는 방법
|
JP2021523138A
(ja)
|
2018-05-11 |
2021-09-02 |
ヤンセン バイオテツク,インコーポレーテツド |
Il−23抗体を使用してうつを治療する方法
|
WO2019225787A1
(ko)
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-b7-h3 항체 및 그 용도
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
EP3820904A2
(en)
|
2018-07-09 |
2021-05-19 |
Five Prime Therapeutics, Inc. |
Antibodies binding to ilt4
|
JP2021530697A
(ja)
|
2018-07-18 |
2021-11-11 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il23特異的抗体で治療した後の持続応答予測因子
|
CN112771075A
(zh)
|
2018-07-30 |
2021-05-07 |
安进研发(慕尼黑)股份有限公司 |
结合至cd33和cd3的双特异性抗体构建体的延长施用
|
PE20211400A1
(es)
|
2018-08-03 |
2021-07-27 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cldn18.2 y cd3
|
US11548938B2
(en)
|
2018-08-21 |
2023-01-10 |
Quidel Corporation |
DbpA antibodies and uses thereof
|
WO2020043670A1
(en)
|
2018-08-27 |
2020-03-05 |
Affimed Gmbh |
Cryopreserved nk cells preloaded with an antibody construct
|
JP2022502076A
(ja)
|
2018-09-18 |
2022-01-11 |
メリマック ファーマシューティカルズ インコーポレーティッド |
抗tnfr2抗体およびその使用
|
CA3113837C
(en)
|
2018-09-24 |
2022-07-12 |
Janssen Biotech, Inc. |
Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
|
MX2021003976A
(es)
|
2018-10-11 |
2021-05-27 |
Amgen Inc |
Procesamiento posterior de constructos de anticuerpos biespecificos.
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
UA127902C2
(uk)
|
2018-10-30 |
2024-02-07 |
Генмаб А/С |
Застосування комбінації антитіла проти vegf і кон'югата антитіло проти тканинного фактора-лікарський засіб для лікування раку
|
CA3117945A1
(en)
|
2018-11-09 |
2020-05-14 |
University Of Massachusetts |
Anti-cfae antibodies and methods of use
|
US11274150B2
(en)
|
2018-11-16 |
2022-03-15 |
Bristol-Myers Squibb Company |
Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies
|
EP3883607A4
(en)
|
2018-11-20 |
2022-08-17 |
Janssen Biotech, Inc. |
SAFE AND EFFECTIVE PROCESS FOR TREATING PSORIASIS WITH A SPECIFIC ANTI-IL-23 ANTIBODY
|
MA54562A
(fr)
|
2018-12-18 |
2021-10-27 |
Janssen Biotech Inc |
Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23
|
WO2020148651A1
(en)
|
2019-01-15 |
2020-07-23 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis
|
SG11202107951YA
(en)
|
2019-01-22 |
2021-08-30 |
Bristol Myers Squibb Co |
Antibodies against il-7r alpha subunit and uses thereof
|
US20220064278A1
(en)
|
2019-01-23 |
2022-03-03 |
Janssen Biotech, Inc. |
Anti-TNF Antibody Compositions for Use in Methods for the Treatment of Psoriatic Arthritis
|
US20220281990A1
(en)
|
2019-03-01 |
2022-09-08 |
Merrimack Pharmaceuticals, Inc. |
Anti-tnfr2 antibodies and uses thereof
|
EP3938391A1
(en)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech, Inc. |
Methods for producing anti-tnf antibody compositions
|
MA55282A
(fr)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech Inc |
Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
|
KR20210141990A
(ko)
|
2019-03-14 |
2021-11-23 |
얀센 바이오테크 인코포레이티드 |
항-il12/il23 항체 조성물을 생성하기 위한 제조 방법
|
EA202192508A1
(ru)
|
2019-03-14 |
2022-03-29 |
Янссен Байотек, Инк. |
Способы получения композиций антитела к фно
|
MA55383A
(fr)
|
2019-03-18 |
2022-01-26 |
Janssen Biotech Inc |
Méthode de traitement du psoriasis chez des sujets pédiatriques avec un anticorps anti-il12/il23
|
KR20210144819A
(ko)
|
2019-03-29 |
2021-11-30 |
브리스톨-마이어스 스큅 컴퍼니 |
크로마토그래피 수지의 소수성을 측정하는 방법
|
CN113874073A
(zh)
|
2019-05-23 |
2021-12-31 |
詹森生物科技公司 |
用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法
|
TW202110877A
(zh)
|
2019-05-30 |
2021-03-16 |
美商安進公司 |
工程改造鉸鏈區以驅動抗體二聚化
|
EP3976648A1
(en)
|
2019-06-03 |
2022-04-06 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
|
JP2022535534A
(ja)
|
2019-06-03 |
2022-08-09 |
ヤンセン バイオテツク,インコーポレーテツド |
活動性強直性脊椎炎を治療するための抗tnf抗体、組成物、及び方法
|
KR20220019785A
(ko)
|
2019-06-12 |
2022-02-17 |
노파르티스 아게 |
나트륨이뇨 펩티드 수용체 1 항체 및 사용 방법
|
CA3137494A1
(en)
|
2019-06-13 |
2020-12-17 |
Amgen Inc. |
Automated biomass-based perfusion control in the manufacturing of biologics
|
CA3143524A1
(en)
|
2019-06-28 |
2020-12-30 |
Amgen Inc. |
Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
|
US20220306734A1
(en)
|
2019-07-24 |
2022-09-29 |
H. Lundbeck A/S |
Anti-mglur5 antibodies and uses thereof
|
JP2022542890A
(ja)
|
2019-07-26 |
2022-10-07 |
アムジエン・インコーポレーテツド |
抗il13抗原結合タンパク質
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
JP2022547135A
(ja)
|
2019-09-10 |
2022-11-10 |
アムジエン・インコーポレーテツド |
増強されたプロテインl捕捉動的結合容量を有する二重特異性抗原結合ポリペプチドの精製方法
|
CN114502590A
(zh)
|
2019-09-18 |
2022-05-13 |
诺华股份有限公司 |
Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
CN115175680A
(zh)
|
2019-10-18 |
2022-10-11 |
加利福尼亚大学董事会 |
Plxdc激活剂及其用于治疗血管病症的用途
|
WO2021091815A1
(en)
|
2019-11-04 |
2021-05-14 |
Seagen Inc. |
Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection
|
MX2022005222A
(es)
|
2019-11-07 |
2022-06-08 |
Genmab As |
Metodos para tratar el cancer con una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y un conjugado de anticuerpo anti factor tisular-farmaco.
|
TW202131954A
(zh)
|
2019-11-07 |
2021-09-01 |
丹麥商珍美寶股份有限公司 |
利用鉑類劑與抗組織因子抗體-藥物共軛體之組合來治療癌症之方法
|
AU2020380379A1
(en)
|
2019-11-08 |
2022-05-26 |
Amgen Inc. |
Engineering charge pair mutations for pairing of hetero-IgG molecules
|
US20220396599A1
(en)
|
2019-11-13 |
2022-12-15 |
Amgen Inc. |
Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules
|
US20230047631A1
(en)
|
2019-11-19 |
2023-02-16 |
Amgen Inc. |
Novel multispecific antibody format
|
JP2023507083A
(ja)
|
2019-12-19 |
2023-02-21 |
クイデル コーポレーション |
モノクローナル抗体融合物
|
JP2023509373A
(ja)
|
2019-12-20 |
2023-03-08 |
ノヴァロック バイオセラピューティクス, リミテッド |
抗インターロイキン-23 p19抗体およびそれの使用方法
|
UY38995A
(es)
|
2019-12-20 |
2021-06-30 |
Amgen Inc |
Constructos de anticuerpo multiespecíficos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores sólidos
|
AU2020414409A1
(en)
|
2019-12-27 |
2022-06-16 |
Affimed Gmbh |
Method for the production of bispecific FcyRIIl x CD30 antibody construct
|
EP4087874A1
(en)
|
2020-01-06 |
2022-11-16 |
HiFiBiO (HK) Limited |
Anti-tnfr2 antibody and uses thereof
|
MX2022008421A
(es)
|
2020-01-07 |
2022-09-23 |
Hifibio Hk Ltd |
Anticuerpo anti-galectina-9 y usos del mismo.
|
WO2021150824A1
(en)
|
2020-01-22 |
2021-07-29 |
Amgen Research (Munich) Gmbh |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
TW202200615A
(zh)
|
2020-03-12 |
2022-01-01 |
美商安進公司 |
用於治療和預防患者的crs之方法
|
KR20220155338A
(ko)
|
2020-03-19 |
2022-11-22 |
암젠 인크 |
뮤신 17에 대한 항체 및 이의 용도
|
JP2023523760A
(ja)
|
2020-05-01 |
2023-06-07 |
ノバルティス アーゲー |
免疫グロブリン変異体
|
JP2023523794A
(ja)
|
2020-05-01 |
2023-06-07 |
ノバルティス アーゲー |
人工操作免疫グロブリン
|
US20230192867A1
(en)
|
2020-05-15 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
CA3183756A1
(en)
|
2020-05-19 |
2021-11-25 |
Amgen Inc. |
Mageb2 binding constructs
|
EP4157874A2
(en)
|
2020-05-29 |
2023-04-05 |
Amgen Inc. |
Adverse effects-mitigating administration of a bispecific antibody construct binding to cd33 and cd3
|
TW202216210A
(zh)
|
2020-06-29 |
2022-05-01 |
丹麥商珍美寶股份有限公司 |
抗組織因子抗體-藥物共軛體類和彼等於治療癌症之用途
|
JP2023534765A
(ja)
|
2020-08-07 |
2023-08-10 |
フォーティス セラピューティクス,インク. |
免疫複合体を標的とするcd46およびその使用方法
|
WO2022033419A2
(en)
|
2020-08-10 |
2022-02-17 |
Shanghai Xbh Biotechnology Co., Ltd. |
Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
|
WO2022040466A1
(en)
|
2020-08-20 |
2022-02-24 |
Amgen Inc. |
Antigen binding proteins with non-canonical disulfide in fab region
|
JP2023540526A
(ja)
|
2020-09-04 |
2023-09-25 |
ノヴァロック バイオセラピューティクス, リミテッド |
ネクチン-4抗体およびそれの使用
|
JP2023544769A
(ja)
|
2020-10-07 |
2023-10-25 |
アムジエン・インコーポレーテツド |
多重特異性抗体の構築のためのビルディングブロックの合理的選択
|
WO2022074206A1
(en)
|
2020-10-08 |
2022-04-14 |
Affimed Gmbh |
Trispecific binders
|
CA3198456A1
(en)
|
2020-10-14 |
2022-04-21 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
WO2022096716A2
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Inc. |
Multitargeting bispecific antigen-binding molecules of increased selectivity
|
JP2023547499A
(ja)
|
2020-11-06 |
2023-11-10 |
ノバルティス アーゲー |
抗体Fc変異体
|
AU2021374036A1
(en)
|
2020-11-06 |
2023-06-08 |
Amgen Inc. |
Polypeptide constructs selectively binding to cldn6 and cd3
|
KR20230098335A
(ko)
|
2020-11-06 |
2023-07-03 |
암젠 인크 |
클리핑 비율이 감소된 항원 결합 도메인
|
US20230406929A1
(en)
|
2020-11-06 |
2023-12-21 |
Amgen Inc. |
Polypeptide constructs binding to cd3
|
AU2021379598A1
(en)
|
2020-11-10 |
2023-06-08 |
Amgen Inc. |
Novel linkers of multispecific antigen binding domains
|
WO2022108931A2
(en)
|
2020-11-17 |
2022-05-27 |
Seagen Inc. |
Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
|
EP4259661A1
(en)
|
2020-12-14 |
2023-10-18 |
Novartis AG |
Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
|
CA3212729A1
(en)
|
2021-03-12 |
2022-09-15 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
|
JP2024510588A
(ja)
|
2021-03-12 |
2024-03-08 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il23特異的抗体による、tnf療法に対する不十分な応答を有する乾癬性関節炎患者を治療する方法
|
AU2022246675A1
(en)
|
2021-04-02 |
2023-10-19 |
Amgen Inc. |
Mageb2 binding constructs
|
EP4324848A1
(en)
|
2021-04-16 |
2024-02-21 |
Korea University Research and Business Foundation |
Human antibody targeting covid-19 virus
|
JP2024515301A
(ja)
|
2021-04-20 |
2024-04-08 |
アムジエン・インコーポレーテツド |
多重特異性及び一価のigg分子の会合における鎖対形成の静電ステアリングにおけるバランスのとれた電荷分布
|
WO2022232376A1
(en)
|
2021-04-29 |
2022-11-03 |
Amgen Inc. |
Methods for reducing low molecular weight species of recombinantly-produced proteins
|
IL307672A
(en)
|
2021-05-06 |
2023-12-01 |
Amgen Res Munich Gmbh |
CD20 and CD22 targeting antigen-binding molecules for use in proliferative diseases
|
KR20240034218A
(ko)
|
2021-07-09 |
2024-03-13 |
얀센 바이오테크 인코포레이티드 |
항-tnf 항체 조성물을 생산하기 위한 제조 방법
|
EP4367137A1
(en)
|
2021-07-09 |
2024-05-15 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
IL309987A
(en)
|
2021-07-09 |
2024-03-01 |
Janssen Biotech Inc |
Production methods for the production of anti-IL12/IL23 antibody compositions
|
AU2022320948A1
(en)
|
2021-07-30 |
2024-01-18 |
Affimed Gmbh |
Duplexbodies
|
IL312110A
(en)
|
2021-10-29 |
2024-06-01 |
Seagen Inc |
Cancer treatment methods with a combination of anti-PD-1 antibody and antibody-CD30 conjugate
|
IL312401A
(en)
|
2021-10-29 |
2024-06-01 |
Janssen Biotech Inc |
Methods for treating Crohn's disease with a specific anti-IL23 antibody
|
CA3233696A1
(en)
|
2021-11-03 |
2023-05-11 |
Joachim Koch |
Bispecific cd16a binders
|
WO2023079493A1
(en)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Bispecific cd16a binders
|
CA3238377A1
(en)
|
2021-11-15 |
2023-05-19 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
CA3239216A1
(en)
|
2021-11-23 |
2023-06-01 |
Janssen Biotech, Inc. |
Method of treating ulcerative colitis with anti-il23 specific antibody
|
US20230312703A1
(en)
|
2022-03-30 |
2023-10-05 |
Janssen Biotech, Inc. |
Method of Treating Psoriasis with IL-23 Specific Antibody
|
TW202400658A
(zh)
|
2022-04-26 |
2024-01-01 |
瑞士商諾華公司 |
靶向il—13和il—18的多特異性抗體
|
TW202408583A
(zh)
|
2022-05-06 |
2024-03-01 |
丹麥商珍美寶股份有限公司 |
使用抗組織因子抗體-藥物共軛體以治療癌症之方法
|
TW202346368A
(zh)
|
2022-05-12 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
|
WO2023223265A1
(en)
|
2022-05-18 |
2023-11-23 |
Janssen Biotech, Inc. |
Method for evaluating and treating psoriatic arthritis with il23 antibody
|
WO2024013724A1
(en)
|
2022-07-15 |
2024-01-18 |
Pheon Therapeutics Ltd |
Antibody-drug conjugates
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
US20240199734A1
(en)
|
2022-11-22 |
2024-06-20 |
Janssen Biotech, Inc. |
Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
|
WO2024127366A1
(en)
|
2022-12-16 |
2024-06-20 |
Pheon Therapeutics Ltd |
Antibodies to cub domain-containing protein 1 (cdcp1) and uses thereof
|